On July 3, Samsung Biologics Co., Ltd. filed a petition with the Korean Intellectual Property Trial and Appeal Board, seeking to invalidate a Korean patent registered to Lonza Biologics PLC related to cell line development.
According to the petition, the patent was granted in Korea in 2007, and its counterparts in the United States, Europe, and Japan were abandoned, withdrawn, or refused.
For more details, please refer the news coverage below:
http://pulsenews.co.kr/view.php?year=2017&no=454024
On July 3, Samsung Biologics Co., Ltd. filed a petition with the Korean Intellectual Property Trial and Appeal Board, seeking to invalidate a Korean patent registered to Lonza Biologics PLC related to cell line development.
According to the petition, the patent was granted in Korea in 2007, and its counterparts in the United States, Europe, and Japan were abandoned, withdrawn, or refused.
For more details, please refer the news coverage below:
http://pulsenews.co.kr/view.php?year=2017&no=454024
Share article
Related Content